Geron Corporation Grants Stock Options to Enhance Talent Acquisition in Biopharmaceuticals

Geron Corporation's Strategic Initiative to Attract Talent through Stock Options

Geron Corporation, a biopharmaceutical company focused on innovative therapies for blood cancers, recently announces a strategic move to enhance its workforce by granting non-statutory stock options to new employees. This initiative is part of its commitment to attract and retain top talent as the company continues to advance its groundbreaking research and drug development. On December 18, 2024, Geron grants options to purchase 72,000 shares of common stock at an exercise price of $3.77, aligning with the stock's closing price on the grant date. The structured options feature a 10-year term, with vesting spread over four years, incentivizing long-term commitment from new hires.

The vesting schedule is designed to motivate employees, with an initial 12.5% of the options vesting six months post-employment, followed by monthly installments of the remaining shares. This strategic approach not only adheres to Nasdaq Listing Rule 5635(c)(4) but also aligns with Geron’s 2018 Inducement Award Plan, which was created to facilitate the granting of stock options. By offering this form of compensation, Geron positions itself as an attractive employer in the competitive biopharmaceutical sector, where talent acquisition is critical to the successful development and commercialization of novel therapies.

As Geron continues to pioneer treatments aimed at changing the treatment paradigm for patients with blood cancers, this initiative highlights the importance of human capital in the company’s growth strategy. The biopharmaceutical industry relies heavily on skilled professionals who can contribute to research and development efforts. By investing in its workforce through stock options, Geron not only fosters employee loyalty but also galvanizes its mission to improve patient outcomes with innovative therapies like its first-in-class telomerase inhibitor, RYTELO™ (imetelstat).

In addition to its talent acquisition efforts, Geron remains focused on expanding its clinical trials for RYTELO™, which has already received U.S. approval for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS). The company is currently conducting a pivotal Phase 3 trial for patients with JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), showcasing its commitment to advancing treatment options for patients suffering from various blood cancers.

Geron’s ongoing exploration of telomerase inhibition continues to position it as a leader in addressing unmet medical needs in hematologic malignancies, reflecting the company's broader mission of transforming the landscape of cancer treatment.